Collaborations
AstraZeneca, Bristol-Myers Squibb announce alliance to develop diabetes compounds
Published in Diabetes Week, February 12th, 2007
Both compounds were discovered by Bristol-Myers Squibb.
Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently in phase III development. Upon successful completion of the development program, the companies plan to file for U.S. regulatory approval of saxagliptin during the first half of 2008. Dapagliflozin (previously referred to as BMS-512148), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is currently in phase IIb development. The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
Source: Diabetes Week (2007-02-12)
More Articles from Diabetes Week
- Drug Development
Insulin sensitizer MBX-102/JNJ-39659100 reduces inflammation in preclinical diabetes models - Atherosclerosis Risk Factors
Study results from Johns Hopkins University, Department of Epidemiology in the area of atherosclerosis risk factors published - Depression Risk Factors
Reports from Norwegian University of Science and Technology advance knowledge in depression risk factors - Depression Therapy
Researchers from University of Louisville discuss findings in depression therapy - Diabetic Retinopathy Cell Biology
Studies from King's College London yield new data on diabetic retinopathy cell biology - Gene Therapy
New gene therapy study findings have been reported by researchers at Genzyme Corporation, Department of Molecular Biology - More from this issue of Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
